» Articles » PMID: 18846346

A Comparative Assessment of the Efficacy of Carbomer Gel and Carboxymethyl Cellulose Containing Artificial Tears in Dry Eyes

Overview
Specialty General Medicine
Date 2008 Oct 11
PMID 18846346
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

The present study aimed to compare the clinical efficacy of a 0.4% carbomer gel and 1% carboxymethyl cellulose (CMC) containing artificial tears in treatment of dry eye patients. Sixty subjects with mean age of 45.89 years who had symptoms and signs of dry eye were enrolled in this prospective, investigator-masked and stratified random sampling study. The subjects were divided into two parallel groups with 30 subjects (60 eyes) in each group. One group received carbomer gel, and the other group received 1% CMC containing artificial tears. Subjects received the drops 3 to 4 times or more per day for 3 months. At the first visit time, the precorneal residence time of these two drops was measured. The efficacy was assessed by comparing the subjective symptoms (ocular dryness, foreign body sensation, burning sensation and pain), and the objective test results of tears breakup time, Schirmer's test and corneal fluorescein staining prior to the study and after the treatment. As a result, the ocular residence time of carbomer gel was significantly longer than that of 1% CMC (P<0.001). Most of the primary subjective symptoms and objective test results were improved after treatment in both carbomer gel group and 1% CMC group. As to the improvement of each symptom and objective test result, carbomer gel was more effective than 1% CMC group (P<0.01). In conclusion, carbomer gel had longer precorneal residence time and was more effective than 1% CMC in the treatment of patients with dry eyes.

Citing Articles

A Critical Appraisal of the Physicochemical Properties and Biological Effects of Artificial Tear Ingredients and Formulations.

Weng J, Fink M, Sharma A Int J Mol Sci. 2023; 24(3).

PMID: 36769079 PMC: 9917348. DOI: 10.3390/ijms24032758.


Artificial Tears: A Systematic Review.

Semp D, Beeson D, Sheppard A, Dutta D, Wolffsohn J Clin Optom (Auckl). 2023; 15:9-27.

PMID: 36647552 PMC: 9840372. DOI: 10.2147/OPTO.S350185.


Efficacy and safety of newly developed preservative-free latanoprost 0.005% eye drops versus preserved latanoprost 0.005% in open angle glaucoma and ocular hypertension: 12-week results of a randomized, multicenter, controlled phase III trial.

Kim J, Sung K, Lee J, Kyung H, Rho S, Kim C Int J Ophthalmol. 2021; 14(10):1539-1547.

PMID: 34667730 PMC: 8482002. DOI: 10.18240/ijo.2021.10.10.


Comparison of the Safety and Efficacy between Preserved and Preservative-Free Latanoprost and Preservative-Free Tafluprost.

Kim J, Park S, Seong M, Ha S, Lee J, Rho S Pharmaceuticals (Basel). 2021; 14(6).

PMID: 34073977 PMC: 8225154. DOI: 10.3390/ph14060501.


The Effect of Artificial Tear Preparations with Three Different Ingredients on Contrast Sensitivity in Patients with Dry Eye Syndrome.

Akkaya S Med Hypothesis Discov Innov Ophthalmol. 2018; 7(2):89-93.

PMID: 30250858 PMC: 6146240.


References
1.
de Paiva C, Chen Z, Koch D, Hamill M, Manuel F, Hassan S . The incidence and risk factors for developing dry eye after myopic LASIK. Am J Ophthalmol. 2006; 141(3):438-45. DOI: 10.1016/j.ajo.2005.10.006. View

2.
Debbasch C, Pisella P, de Saint Jean M, Rat P, Warnet J, Baudouin C . Mitochondrial activity and glutathione injury in apoptosis induced by unpreserved and preserved beta-blockers on Chang conjunctival cells. Invest Ophthalmol Vis Sci. 2001; 42(11):2525-33. View

3.
Lenton L, Albietz J . Effect of carmellose-based artificial tears on the ocular surface in eyes after laser in situ keratomileusis. J Refract Surg. 1999; 15(2 Suppl):S227-31. DOI: 10.3928/1081-597X-19990302-17. View

4.
Miljanovic B, Dana R, Sullivan D, Schaumberg D . Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol. 2007; 143(3):409-15. PMC: 1847608. DOI: 10.1016/j.ajo.2006.11.060. View

5.
Schaumberg D, Buring J, Sullivan D, Dana M . Hormone replacement therapy and dry eye syndrome. JAMA. 2001; 286(17):2114-9. DOI: 10.1001/jama.286.17.2114. View